CN108463468B - 一种人胰岛素或其类似物的酰化衍生物 - Google Patents

一种人胰岛素或其类似物的酰化衍生物 Download PDF

Info

Publication number
CN108463468B
CN108463468B CN201780005001.7A CN201780005001A CN108463468B CN 108463468 B CN108463468 B CN 108463468B CN 201780005001 A CN201780005001 A CN 201780005001A CN 108463468 B CN108463468 B CN 108463468B
Authority
CN
China
Prior art keywords
human insulin
ins
zinc complex
acylated derivative
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780005001.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108463468A (zh
Inventor
刘德玉
王宏伟
赵亮
王菲菲
曾翔
王涛
王亚里
戴雨璐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN202210131921.6A priority Critical patent/CN114478747B/zh
Publication of CN108463468A publication Critical patent/CN108463468A/zh
Application granted granted Critical
Publication of CN108463468B publication Critical patent/CN108463468B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201780005001.7A 2016-08-02 2017-08-01 一种人胰岛素或其类似物的酰化衍生物 Active CN108463468B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210131921.6A CN114478747B (zh) 2016-08-02 2017-08-01 一种人胰岛素或其类似物的酰化衍生物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610625257 2016-08-02
CN2016106252575 2016-08-02
CN201610779132 2016-08-31
CN2016107791328 2016-08-31
PCT/CN2017/095377 WO2018024186A1 (zh) 2016-08-02 2017-08-01 一种人胰岛素或其类似物的酰化衍生物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210131921.6A Division CN114478747B (zh) 2016-08-02 2017-08-01 一种人胰岛素或其类似物的酰化衍生物

Publications (2)

Publication Number Publication Date
CN108463468A CN108463468A (zh) 2018-08-28
CN108463468B true CN108463468B (zh) 2022-03-04

Family

ID=61074099

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210131921.6A Active CN114478747B (zh) 2016-08-02 2017-08-01 一种人胰岛素或其类似物的酰化衍生物
CN201780005001.7A Active CN108463468B (zh) 2016-08-02 2017-08-01 一种人胰岛素或其类似物的酰化衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210131921.6A Active CN114478747B (zh) 2016-08-02 2017-08-01 一种人胰岛素或其类似物的酰化衍生物

Country Status (6)

Country Link
US (1) US10815287B2 (enExample)
EP (1) EP3495384A4 (enExample)
JP (2) JP7432361B2 (enExample)
CN (2) CN114478747B (enExample)
TW (1) TWI747929B (enExample)
WO (1) WO2018024186A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3747896A4 (en) * 2018-02-01 2021-11-24 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL COMPOSITION OF ACYLATED DERIVATIVE OF HUMAN INSULIN ANALOGUE AND MANUFACTURING PROCESS FOR IT
US20210032307A1 (en) 2018-02-09 2021-02-04 Jiangsu Hengrui Medicine Co., Ltd. Codon optimized precursor gene and signal peptide gene of human insulin analogue
BR112020023485A2 (pt) 2018-05-24 2021-03-30 Jiangsu Hengrui Medicine Co., Ltd. Métodos para preparar um precursor de insulina humana recombinante ou análogo da mesma, insulina humana recombinante ou análogo da mesma e análogo de insulina acilado
CA3122636A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin analogs having reduced insulin receptor binding affinity
CN118894922A (zh) * 2019-12-30 2024-11-05 甘李药业股份有限公司 胰岛素衍生物
WO2022111642A1 (zh) * 2020-11-27 2022-06-02 江苏恒瑞医药股份有限公司 一种制备胰岛素或其类似物的酰化衍生物的方法
CN112939771A (zh) * 2021-01-28 2021-06-11 宁夏蓝博思化学技术有限公司 长链烷基二酸单叔丁酯的制备方法
CA3217734A1 (en) 2021-05-24 2022-12-01 Baoye ZHENG A novel acylated insulin analog
CA3228912A1 (en) 2021-06-25 2022-12-29 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin-containing pharmaceutical composition
EP4471053A1 (en) 2022-01-28 2024-12-04 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1163574A (zh) * 1994-11-17 1997-10-29 伊莱利利公司 酰化的胰岛素类似物
EP1132404A2 (en) * 1993-09-17 2001-09-12 Novo Nordisk A/S Acylated insulin
CN101389650A (zh) * 2005-12-28 2009-03-18 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
WO2013086927A1 (zh) * 2011-12-15 2013-06-20 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
AU2003208316A1 (en) * 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
JP4463814B2 (ja) * 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
EP2287184A3 (en) * 2003-08-05 2011-08-10 Novo Nordisk A/S Novel insulin derivatives
EP2178910B1 (en) * 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
MX2010009850A (es) * 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
US8935928B2 (en) * 2011-10-10 2015-01-20 Lockheed Martin Corporation Integrated air-cycle refrigeration and power generation system
WO2017136834A1 (en) * 2016-02-05 2017-08-10 Memorial Sloan-Ketering Cancer Center Methods of differentiating stem cell-derived ectodermal lineage precursors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132404A2 (en) * 1993-09-17 2001-09-12 Novo Nordisk A/S Acylated insulin
CN1163574A (zh) * 1994-11-17 1997-10-29 伊莱利利公司 酰化的胰岛素类似物
CN101389650A (zh) * 2005-12-28 2009-03-18 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
WO2013086927A1 (zh) * 2011-12-15 2013-06-20 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法

Also Published As

Publication number Publication date
JP7432361B2 (ja) 2024-02-16
TW201805300A (zh) 2018-02-16
JP2022095872A (ja) 2022-06-28
CN114478747B (zh) 2024-06-14
EP3495384A1 (en) 2019-06-12
US10815287B2 (en) 2020-10-27
CN114478747A (zh) 2022-05-13
TWI747929B (zh) 2021-12-01
CN108463468A (zh) 2018-08-28
JP2019526537A (ja) 2019-09-19
WO2018024186A1 (zh) 2018-02-08
US20190169257A1 (en) 2019-06-06
EP3495384A4 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
CN108463468B (zh) 一种人胰岛素或其类似物的酰化衍生物
JP6084215B2 (ja) ポリエチレングリコールまたはその誘導体でｐｅｇ化されたエキセンジン−４類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
JP5269766B2 (ja) インスリン誘導体
JP5269767B2 (ja) インスリン誘導体
WO2014093696A2 (en) Insulin derivatives for diabetes treatment
WO2012130015A1 (zh) 定点单取代聚乙二醇化Exendin类似物及其制备方法
CN115385843A (zh) 一种新型的酰化胰岛素类似物
JP2025525218A (ja) インクレチンアナログおよびその使用
CN111315766B (zh) 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法
CN109248323A (zh) 酰化的glp-1衍生物
HK1255297B (en) Acylated derivative of human insulin or analogue thereof
HK1255297A1 (en) Acylated derivative of human insulin or analogue thereof
CN118791591A (zh) 门冬胰岛素、门冬胰岛素复合物及其制备方法和应用
KR100746658B1 (ko) 소수성 담즙산이 접합된 엑센딘-4 유도체, 이의 제조방법및 이를 포함하는 약학 조성물
HK40032575A (en) Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof
CN101437849B (zh) 胰岛素衍生物
CN111234000B (zh) 艾塞纳肽类似物
HK40032575B (en) Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof
HK40069563B (zh) Glp-1和gip受体双重激动剂化合物及其应用
FR3074422A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
HK1162526A1 (en) Glp-1 derivatives and uses thereof
HK1162037B (en) Glucagon-like peptide-1 analogue and use thereof
HK1162526B (en) Glp-1 derivatives and uses thereof
HK1162037A1 (en) Glucagon-like peptide-1 analogue and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255297

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant